Reinsurance Commissions, fees and other revenue decreased 2% in 2014 reflecting a 1% unfavorable impact from foreign currency exchange rates and 1% decline in organic revenue growth due primarily to a significant unfavorable market impact in treaty, partially offset by net new business growth in treaty placements globally and growth in capital markets transactions and advisory business, as well as facultative placements.
Operating Income Operating income increased $108 million, or 7%, from 2013 to $1.6 billion in 2014.
In 2014, operating income margins in this segment were 21.0%, an increase of 120 basis points from 19.8% in 2013.
Operating margin improvement was driven by solid organic revenue growth, return on investments, expense discipline and savings related to the restructuring programs, partially offset by a $61 million unfavorable impact from foreign currency exchange rates.
HR Solutions Years ended
## Table 0 ##
Our HR Solutions segment generated approximately 35% of our consolidated total revenues in 2014 and provides a broad range of human capital services, as follows: ?
Retirement specializes in global actuarial services, defined contribution consulting, tax and ERISA consulting, and pension administration.  ?
Compensation focuses on compensatory advisory/counsel including: compensation planning design, executive reward strategies, salary survey and benchmarking, market share studies and sales force effectiveness, with special expertise in the financial services and technology industries.  ?
Strategic Human Capital delivers advice to complex global organizations on talent, change and organizational effectiveness issues, including talent strategy and acquisition, executive on-boarding, performance management, leadership assessment and development, communication strategy, workforce training and change management.  ?
Investment consulting advises public and private companies, other institutions and trustees on developing and maintaining investment programs across a broad range of plan types, including defined benefit plans, defined contribution plans, endowments and foundations.  ?
Benefits Administration applies our human resource expertise primarily through defined benefit (pension), defined contribution (401(k)), and health and welfare administrative services.
Our model replaces the resource-intensive processes once required to administer benefit plans with more efficient, effective, and less costly solutions.  ?
Exchanges is building and operating healthcare exchanges that provide employers with a cost effective alternative to traditional employee and retiree healthcare, while helping individuals select the insurance that best meets their needs.  ?
Human Resource Business Processing Outsourcing provides market-leading solutions to manage employee data; administer benefits, payroll and other human resources processes; and record and manage talent, workforce and other core human resource process transactions as well as other complementary services such as flexible spending, dependent audit and participant advocacy.
Disruption in the global credit markets and the deterioration of the financial markets created significant uncertainty in the marketplace.
Weak economic conditions in many markets around the globe continued throughout 2014 and have adversely impacted our clients' financial condition and therefore the levels of business activities in the industries and geographies where we operate.
While we believe that the majority of our practices are well positioned to manage through this time, these challenges are reducing demand for some of our services and putting continued pressure on the pricing of those services, which is having an adverse effect on our new business and results of operations.
Bristol-Myers Squibb 104 The Company’s investment strategy emphasizes equities in order to achieve high expected returns and, in the long run, low expense and low required cash contributions.
For the U. S.  pension plans, a target asset allocation of 70% public equity (58% U. S. , 12% international), 8% private equity and 22% fixed income is maintained and cash flow (i. e. , cash contributions, benefit payments) is used to rebalance back to the targets as necessary.
Investments are very well diversified within each of the three major asset categories.
About 40% of the U. S.  equity is passively managed.
Otherwise, all investments are actively managed.
Investment strategies for international pension plans are typically similar, although the asset allocations are usually more conservative.
Bristol–Myers Squibb Company common stock represents less than 1% of the plan assets at December 31, 2005 and 2004.
Assets for postretirement benefits are commingled with U. S.  pension plan assets and, therefore, the investment strategy is identical to that described above for U. S.  pension plans.
Contributions Although no minimum contributions will be required, the Company plans to make cash contributions to the U. S.  pension plans in 2006.
When contributions are made to the U. S.  pension plans, the Company may make tax-deductible contributions to the 401(h) account for retiree medical benefits equal to a portion of the pension normal cost.
Contributions to the international pension plans are now expected to be in the $70 to $90 million range for 2006.
Estimated Future Benefit Payments The following benefit payments for mainly the U.
S pension plans, which reflect expected future service, as appropriate, are expected to be paid:
## Table 1 ##
Savings Plan The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program.
The Company’s contribution is based on employee contributions and the level of Company match.
The Company’s contributions to the plan were $51 million in 2005, $53 million in 2004 and $51 million in 2003.
Termination Indemnity Plans The Company operates in certain jurisdictions, primarily in Europe, which require the recording of statutory termination obligations.
These obligations were assessed in accordance with EITF 88-1, Determination of Vested Benefit Obligation for a Defined Benefit Pension Plan.
The total liability recorded for these obligations was $68 million at December 31, 2005 and $81 million at December 31, 2004.
Note 20 Legal Proceedings and Contingencies Various lawsuits, claims, proceedings and investigations are pending against the Company and certain of its subsidiaries.
In accordance with SFAS No.5, Accounting for Contingencies, the Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.
These matters involve antitrust, securities, patent infringement, pricing, sales and marketing practices, environmental, health and safety matters, product liability and insurance coverage.
The most significant of these matters are described below.
There can be no assurance that there will not be an increase in the scope of these matters or that any future lawsuits, claims, proceedings or investigations will not be material.
Management continues to believe, as previously disclosed, that during the next few years, the aggregate impact, beyond current reserves, of these and other legal matters affecting the Company is reasonably likely to be material to the Company’s results of operations and cash flows, and may be material to its financial condition and liquidity.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made.
As a result of external factors, the availability of insurance has become more restrictive while the cost has increased significantly.
The Company has evaluated its risks and has determined that the cost of obtaining insurance outweighs the benefits of coverage protection against losses and as such, became self-insured for product liabilities effective July 1, 2004.
The Company will continue to evaluate these risks and benefits to determine its insurance needs in the future.
Bristol-Myers Squibb 36 RESULTS OF OPERATIONS The following discussion of the Company’s results of continuing operations excludes the results related to the Oncology Therapeutics Network (OTN) business, which were previously presented as a separate segment, and has been segregated from continuing operations and reflected as discontinued operations for all periods presented.
See “—Discontinued Operations” below.
## Table 2 ##
Net Sales Net sales from continuing operations for 2005 decreased 1% to $19.2 billion compared to 2004.
U. S.  net sales in 2005 decreased 1% to $10.5 billion compared to 2004, while international net sales of $8.7 billion remained relatively constant in 2005 as compared to 2004, including a 2% favorable foreign exchange impact.
In 2004, net sales from continuing operations increased 4% to $19.4 billion from $18.7 billion in 2003.
U. S.  net sales in 2004 remained relatively constant at $10.6 billion compared to 2003 and international net sales increased 10% to $8.8 billion in 2004, including a 8% favorable foreign exchange impact, from $8.0 billion in 2003.
The composition of the change in sales is as follows:
## Table 3 ##
In general, the Company’s business is not seasonal.
For information on U. S.  pharmaceuticals prescriber demand, reference is made to the table within Business Segments under the Pharmaceuticals section below, which sets forth a comparison of changes in net sales to the estimated total prescription growth (for both retail and mail order customers) for certain of the Company’s pharmaceutical products.
The Company operates in three reportable segments—Pharmaceuticals, Nutritionals and Other Health Care.
In May 2005, the Company completed the sale of OTN, which was previously presented as a separate segment.
As such, the results of operations for OTN are presented as part of the Company’s results from discontinued operations in accordance with Statement of Financial Standards (SFAS) No.144, “Accounting for the Impairment or Disposal of Long-Lived Assets.
” Accordingly, OTN results of operations in prior periods have been reclassified to discontinued operations to conform with current year presentations.
The percent of the Company’s net sales by segment were as follows:
## Table 4 ##
The following table summarizes the Company’s results on a pro forma basis as if it had recorded compensation expense based upon the fair value at the grant date for awards under these plans consistent with the methodology prescribed in SFAS No.123 for 2005, 2004 and 2003:

<table><tr><td>Years ended December 31</td><td>2014</td><td>2013</td><td>2012</td></tr><tr><td>Revenue</td><td>$4,264</td><td>$4,057</td><td>$3,925</td></tr><tr><td>Operating income</td><td>485</td><td>318</td><td>289</td></tr><tr><td>Operating margin</td><td>11.4%</td><td>7.8%</td><td>7.4%</td></tr></table>
<table><tr><td></td><td></td><td colspan="3"> Other Benefits </td></tr><tr><td>(Dollars in Millions)</td><td> Pension Benefits </td><td> Gross </td><td> Medicare Subsidy </td><td> Net </td></tr><tr><td>2006</td><td>$280</td><td>$67</td><td>$7</td><td>$60</td></tr><tr><td>2007</td><td>300</td><td>65</td><td>8</td><td>57</td></tr><tr><td>2008</td><td>324</td><td>64</td><td>8</td><td>56</td></tr><tr><td>2009</td><td>338</td><td>64</td><td>9</td><td>55</td></tr><tr><td>2010</td><td>357</td><td>62</td><td>9</td><td>53</td></tr><tr><td>Years 2011 – 2015</td><td>2,159</td><td>293</td><td>51</td><td>242</td></tr></table>
<table><tr><td></td><td colspan="2"></td><td></td><td colspan="2">% Change</td></tr><tr><td>(Dollars in Millions)</td><td>2005</td><td>2004</td><td>2003</td><td>2005 to 2004</td><td>2004 to 2003</td></tr><tr><td>Net Sales</td><td>$19,207</td><td>$19,380</td><td>$18,653</td><td>-1%</td><td>4%</td></tr><tr><td>Earnings from Continuing Operations Before Minority Interest and Income Taxes</td><td>$4,516</td><td>$4,418</td><td>$4,680</td><td>2%</td><td>-6%</td></tr><tr><td><i>% of net sales</i></td><td>23.5%</td><td>22.8%</td><td>25.1%</td><td></td><td></td></tr><tr><td>Provision for income taxes</td><td>$932</td><td>$1,519</td><td>$1,210</td><td>-39%</td><td>26%</td></tr><tr><td><i>Effective tax rate</i></td><td>20.6%</td><td>34.4%</td><td>25.8%</td><td></td><td></td></tr><tr><td>Earnings from Continuing Operations</td><td>$2,992</td><td>$2,378</td><td>$3,097</td><td>26%</td><td>-23%</td></tr><tr><td><i>% of net sales</i></td><td>15.6%</td><td>12.3%</td><td>16.6%</td><td></td><td></td></tr></table>
<table><tr><td></td><td></td><td colspan="3"> Analysis of % Change </td></tr><tr><td></td><td> Total Change </td><td> Volume </td><td> Price </td><td> Foreign Exchange </td></tr><tr><td>2005 vs. 2004</td><td>-1%</td><td>-2%</td><td>—</td><td>1%</td></tr><tr><td>2004 vs. 2003</td><td>4%</td><td>—</td><td>—</td><td>4%</td></tr></table>
<table><tr><td></td><td colspan="3">Net Sales</td><td colspan="2">% Change</td></tr><tr><td>(Dollars in Millions)</td><td>2005</td><td>2004</td><td>2003</td><td>2005 to 2004</td><td>2004 to 2003</td></tr><tr><td>Pharmaceuticals</td><td>$15,254</td><td>$15,564</td><td>$15,025</td><td>-2%</td><td>4%</td></tr><tr><td><i>% of net sales</i></td><td>79%</td><td>80%</td><td>80%</td><td></td><td></td></tr><tr><td>Nutritionals</td><td>2,205</td><td>2,001</td><td>2,023</td><td>10%</td><td>-1%</td></tr><tr><td><i>% of net sales</i></td><td>12%</td><td>10%</td><td>11%</td><td></td><td></td></tr><tr><td>Other Health Care</td><td>1,748</td><td>1,815</td><td>1,605</td><td>-4%</td><td>13%</td></tr><tr><td><i>% of net sales</i></td><td>9%</td><td>10%</td><td>9%</td><td></td><td></td></tr><tr><td>Total</td><td>$19,207</td><td>$19,380</td><td>$18,653</td><td>-1%</td><td>4%</td></tr></table>

Question: Which year is Other Health Care the most for Net Sales?
Answer: 2004